Antiviral therapy for chronic hepatitis B in China

Medical Microbiology and Immunology

Volumn 204, Issue 1, 2015, Pages 115-120

  Zheng, Xin ^a   Wang, Junzhong ^a   Yang, Dongliang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antiviral therapy; China; Chronic hepatitis B; Drug resistance

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MATRINE; NUCLEOSIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; ANTIVIRAL THERAPY; BUPLEURUM; CHINA; CHINESE MEDICINE; CHRONIC LIVER DISEASE; DISEASE COURSE; HEPATITIS B; HUMAN; LIVER FUNCTION; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHUBARB; SEROCONVERSION; VIRUS STRAIN; DRUG THERAPY; DRUG UTILIZATION; ECONOMICS; HEALTH CARE DELIVERY; HEPATITIS B, CHRONIC; PROCEDURES;

ANTIVIRAL AGENTS; CHINA; DRUG THERAPY; DRUG UTILIZATION; HEALTH SERVICES ACCESSIBILITY; HEPATITIS B, CHRONIC; HUMANS;

EID: 84925507305     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-014-0380-z     Document Type: Review

References (41)

1. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association (2011) The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 19:13–24
2. Lok AS (2013) Hepatitis: long-term therapy of chronic hepatitis B reverses cirrhosis. Nat Rev Gastroenterol Hepatol 10:199–200
3. Liaw YF (2013) Reduction of cirrhosis and hepatocellular carcinoma with antiviral therapy in chronic hepatitis B. Hepatology 58:1856
4. Liaw YF (2013) Impact of therapy on the outcome of chronic hepatitis B. Liver Int 33(Suppl 1):111–115
5. Sun J, Hou JL (2010) Management of chronic hepatitis B: experience from China. J Viral Hepat 17(Suppl 1):10–17
6. Karmen A, Wroblewski F, Ladue JS (1955) Transaminase activity in human blood. J Clin Invest 34:126–131
7. Kaplan MM (2002) Alanine aminotransferase levels: what’s normal? Ann Intern Med 137:49–51
8. Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Hai-Jun H (2013) Comparison of histologic characteristics of chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS ONE 8:e80585
9. Gui HL, Wang H, Yang YH, Wu YW, Zhou HJ, Guo SM, Lin LY et al (2010) Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. J Viral Hepat 17(Suppl 1):44–50
10. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L et al (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1–10
11. Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50:661–662
12. Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, Chung YH et al (2010) Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 51:1577–1583
13. Korean Association for the Study of the Liver (2012) KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 18:109–162
14. Zheng MH, Shi KQ, Fan YC, Liu WY, Lin XF, Li LF, Chen YP (2012) Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population. PLoS ONE 7:e43736
15. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123–129
16. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM et al (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351:1206–1217
17. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001–1010
18. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH et al (2007) Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133:1437–1444
19. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G et al (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442–2455
20. European Association For The Study Of The Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167–185
21. Dong PL, Wang DM, Zhang XM, Zhang B, Ding HG, Min J, Chen XY (2009) Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 23:473–475
22. Zhao H, Zhang YX, Chen XY, Wang L, Tang XP, Si CW (2007) A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B. Zhonghua Nei Ke Za Zhi 46:294–297
23. Wang H, Wang QH, Wang HF, Jia JD, Xie W, Qin XQ (2004) A clinical study of the efficacy and safety of secretory human interferon alpha-2a treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 12:589–592
24. Wong VW, Law MY, Hui AY, Lo AO, Li CY, Soo MT, Leung HY et al (2005) A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. Complement Ther Med 13:175–182
25. Chen Y, Zhu J (2013) Anti-HBV effect of individual traditional Chinese herbal medicine in vitro and in vivo: an analytic review. J Viral Hepat 20:445–452
26. He J, Zhou D, Tong G, Xing Y, Chen Y, Zhang X, Zhan B et al (2013) Efficacy and safety of a chinese herbal formula (invigorating kidney and strengthening spleen) in chronic hepatitis B virus carrier: results from a multicenter, randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med 2013:961926
27. Ma ZJ, Li Q, Wang JB, Zhao YL, Zhong YW, Bai YF, Wang RL et al (2013) Combining oxymatrine or matrine with lamivudine increased its antireplication effect against the hepatitis B virus in vitro. Evid Based Complement Alternat Med 2013:186573
28. Guo Z, Yu S, Guan Y, Li YY, Lu YY, Zhang H, Su SB (2012) Molecular mechanisms of same TCM syndrome for different diseases and different TCM syndrome for same disease in chronic hepatitis B and liver cirrhosis. Evid Based Complement Alternat Med 2012:120350
29. Wang R, Kong J, Wang D, Lien LL, Lien EJ (2007) A survey of Chinese herbal ingredients with liver protection activities. Chin Med 2:5
30. Xu XH, Li GL, Qin Y, Li Q, He FQ, Li JY, Pan QR et al (2013) Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice. Virol J 10:162
31. Ha M, Zhang G, Diao S, Lin M, Wu J, Sun L, She H et al (2012) Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy. Intern Med 51:1509–1515
32. Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H (2013) Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. J Viral Hepat 20(Suppl 1):40–45
33. Zhang Y, Lian JQ, Li Y, Wang JP, Huang CX, Bai XF (2013) Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. Eur J Gastroenterol Hepatol 25:814–819
34. Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R et al (2013) 104-week efficacy and safety of telbivudine based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology 59:1283–1292
35. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M (2007) Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445–1451
36. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosgart CL et al (2008) Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 48:728–735
37. Cao Z, Zhang Y, Ma L, Sun G, He Z, Liu Y, Jin Y et al (2010) Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40KD] (PEGASYS) plus lamivudine or adefovir for 96 weeks results in high rates of HBsAg clearance/seroconversion. Hepatology 52(suppl 1):507A
38. He Z, Wang J, Liu K, Huang H, Du Y, Lin Z, Cai M et al (2012) Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. Clin Res Hepatol Gastroenterol 36:592–597
39. Li Y, Chen ZT, Wu JC, Gan JH, Chen JJ, Zhao WF, Luo EP (2012) Efficacy and safety of telbivudine and adefovir dipivoxil for the treatment of chronic hepatitis B patients with high level hepatitis B virus load and hepatitis B e antigen-positivity. Zhonghua Gan Zang Bing Za Zhi 20:859–860
40. Zeng W, Yuan J, Liu YX, Zhang Y, Li SX, Yao SM, Lin YM et al (2013) Efficacy of Peg-interferon alpha-2a combinated with entecavir on HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 27:115–118
41. Ma W, Zhou B, Ao F, Zhou D, Hu Y, He Q, Dai W et al (2009) Higher sustained post-treatment virologic response following peginterferon alfa-2a ± adefovir compared with adefovir monotherapy in HBeAg-positive patients. Hepatology 50(Suppl 5):494A